Van Maanen M.A.,University of Amsterdam |
Stoof S.P.,University of Amsterdam |
LaRosa G.J.,Cornerstone Therapeutics |
Vervoordeldonk M.J.,University of Amsterdam |
Tak P.P.,University of Amsterdam
Annals of the Rheumatic Diseases | Year: 2010
Background: The α7 subunit of nicotinic acetylcholine receptors (α7nAChR) can negatively regulate the synthesis and release of proinflammatory cytokines by macrophages and fibroblast-like synoviocytes in vitro. In addition, stimulation of the α7nAChR can reduce the severity of arthritis in murine collagen-induced arthritis (CIA). Objective: To provide more insight into the role of the α7nAChR in the pathogenesis of arthritis by investigating the effect of the absence of α7nAChR in CIA in α7-deficient (α7nAChR-/-) compared with wild-type (WT) mice. Methods: CIA was induced in α7nAChR-/- and WT littermate mice at day 0 by immunisation with chicken collagen type II (cCII) followed by a booster injection with cCII on day 20. Mice were killed on day 44 or day 63 and arthritis activity as well as radiological and histological damage were scored. The effects on the immune response were evaluated by measurement of antigen-specific antibodies and cytokines, and evaluation of the effects on antigen-specific stimulated spleen cells. Results: In α7nAChR -/- mice a significant increase in the incidence and severity of arthritis as well as increased synovial inflammation and joint destruction were seen. Exacerbation of CIA was associated with elevated systemic proinflammatory cytokines and enhanced T-helper cell 1 (Th1)-cytokine and tumour necrosis factor α production by spleen cells. Moreover, a specific decrease in the collagen-specific 'Th1-associated' IgG2a response was seen, whereas IgG1 titres were unaffected. Conclusions: The results presented here indicate that immune cell function in a model of rheumatoid arthritis is regulated by the cholinergic system and, at least in part, mediated by the α7nAChR. Source
Cornerstone Therapeutics | Date: 2011-11-23
Cornerstone Therapeutics | Date: 2012-05-23
Cornerstone Therapeutics | Date: 2014-07-29
Disclosed are novel piperazine derivatives that act as agonists of the 7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.
Cornerstone Therapeutics | Date: 2012-01-09
Pharmaceutical preparations for the treatment of cardiovascular disorders.